Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Depreciation and Depletion (2016 - 2020)

Historic Depreciation and Depletion for Ptc Therapeutics (PTCT) over the last 9 years, with Q4 2020 value amounting to -$24.5 million.

  • Ptc Therapeutics' Depreciation and Depletion fell 3452.73% to -$24.5 million in Q4 2020 from the same period last year, while for Dec 2020 it was $6.6 million, marking a year-over-year increase of 4042.55%. This contributed to the annual value of $14.9 million for FY2024, which is 719.42% up from last year.
  • As of Q4 2020, Ptc Therapeutics' Depreciation and Depletion stood at -$24.5 million, which was down 3452.73% from $11.6 million recorded in Q3 2020.
  • Ptc Therapeutics' Depreciation and Depletion's 5-year high stood at $11.6 million during Q3 2020, with a 5-year trough of -$24.5 million in Q4 2020.
  • In the last 5 years, Ptc Therapeutics' Depreciation and Depletion had a median value of $3.4 million in 2016 and averaged $975000.0.
  • Data for Ptc Therapeutics' Depreciation and Depletion shows a peak YoY increase of 116629.77% (in 2017) and a maximum YoY decrease of 124738.76% (in 2017) over the last 5 years.
  • Ptc Therapeutics' Depreciation and Depletion (Quarter) stood at $823000.0 in 2016, then plummeted by 1247.39% to -$9.4 million in 2017, then tumbled by 77.02% to -$16.7 million in 2018, then dropped by 8.9% to -$18.2 million in 2019, then tumbled by 34.53% to -$24.5 million in 2020.
  • Its last three reported values are -$24.5 million in Q4 2020, $11.6 million for Q3 2020, and $10.2 million during Q2 2020.